|By PR Newswire||
|September 26, 2013 02:00 PM EDT||
NEW HAVEN, Conn., Sept. 26, 2013 /PRNewswire/ -- Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced it has raised $15 million in Series A funds and $4.25 million in financial support, $1 million of which is in the form of equity, from the Connecticut Department of Economic and Community Development and Connecticut Innovations. Investors in the Series A round include co-leads Canaan Partners and 5AM Ventures along with Connecticut Innovations and Elm Street Ventures. The funds will support the development of the company's technology which has primary application in multiple oncology indications and potential in inflammatory, autoimmune and rare diseases.
Arvinas is built on the research of Craig Crews, PhD, Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and professor of Chemistry and Pharmacology at Yale University. The new drugs being developed by Arvinas would induce a cell's own protein-degradation capabilities to bind to a particular protein and "label" it for degradation, thus removing a protein from the system entirely. This contrasts to a more traditional drug development approach that inhibits proteins. However, only 25 percent of the body's 20,000 proteins can be inhibited. Proteins that cannot be inhibited can potentially be degraded using Arvinas' approach, radically expanding the number of disease-causing proteins that can become the targets of new drugs.
"Degrading proteins as opposed to inhibiting them has potential to open up areas of drug development that were previously closed because of the technical limitations of protein inhibition," said Tim Shannon, MD, CEO of Arvinas and Venture Partner at Canaan Partners. "The Arvinas technology platform represents an entirely new class of drugs bringing an innovative approach to treating disease."
"In addition to the fact that a very large portion of proteins cannot be blocked, inhibition is not permanent, so a disease-causing protein can eventually become active again after treatment with a drug," said Dr. Crews. "To effectively stop cancer, a drug-binding site must be inhibited 95 percent of the time, which is currently difficult to achieve. If a protein is removed entirely, that should overcome this problem."
Arvinas also announced the formation of a Scientific Advisory Board (SAB), which will help guide the development of its novel approach. Members of the SAB include Daniel D. Von Hoff, MD, Chief, distinguished professor and director of clinical translational research division at the Translational Genomics Research Institute and Chief Scientific Officer for US Oncology; Mark Murcko, PhD, former Chief Technology Officer at Vertex Pharmaceuticals; Thomas J. Lynch, Jr., MD, Director of the Yale Cancer Center and Physician-in-chief at Smilow Cancer Hospital at Yale-New Haven; Richard Ulevitch, Venture Partner 5AM and Professor and Chairman Emeritus of the Department of Immunology at The Scripps Research Institute, La Jolla, California; and Peter Farina, PhD, executive in residence at Canaan Partners and former Senior Vice-President of Development at Boehringer Ingelheim.
Arvinas worked with the Yale Office of Cooperative Research (OCR) to secure intellectual property protection for the technology.
"The Arvinas team has lined up an impressive slate of supporters of the unique technology that comes out of Yale University," noted John Soderstrom, PhD, Managing Director of the Office of Cooperative Research at Yale and a member of Arvinas' Board of Directors. "Degrading proteins that are driving disease has the potential to bring about drastic changes in drug development, and we anticipate significant interest from pharmaceutical companies."
Joining Dr. Shannon and Dr. Soderstrom on the Arvinas Board of Directors will be Kush Parmar, MD PhD and a Principal at 5AM Ventures and Brad Margus, the CEO of Genome Bridge and former CEO of Envoy Therapeutics.
About the Yale Office of Cooperative Research
The Yale Office of Cooperative Research works with faculty to realize the commercial potential of their discoveries through licensing of intellectual property, identification of opportunities to partner with corporate sponsors of research and facilitating the formation of new ventures based on Yale's intellectual property. Learn more at http://www.yale.edu/ocr.
Arvinas Inc. is creating a new class of drugs based on protein degradation, which has the potential to open up areas of drug development that were previously closed because of the technical limitations of target inhibition. The company's technology is built on the research of Craig Crews, PhD of Yale University and has primary application in oncology indications as well as potential in inflammatory, autoimmune and rare diseases. http://www.arvinas.com/
SOURCE Arvinas Inc.
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
Apr. 26, 2017 07:45 PM EDT Reads: 640
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
Apr. 26, 2017 07:15 PM EDT Reads: 9,054
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...
Apr. 26, 2017 06:30 PM EDT Reads: 2,252
SYS-CON Events announced today that Twistlock, the leading provider of cloud container security solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Twistlock is the industry's first enterprise security suite for container security. Twistlock's technology addresses risks on the host and within the application of the container, enabling enterprises to consistently enforce security policies, monitor...
Apr. 26, 2017 06:30 PM EDT Reads: 3,696
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
Apr. 26, 2017 06:15 PM EDT Reads: 2,413
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
Apr. 26, 2017 06:15 PM EDT Reads: 2,220
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Apr. 26, 2017 06:15 PM EDT Reads: 792
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
Apr. 26, 2017 05:45 PM EDT Reads: 677
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
Apr. 26, 2017 05:45 PM EDT Reads: 2,255
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Apr. 26, 2017 05:30 PM EDT Reads: 2,152
@ThingsExpo has been named the Most Influential ‘Smart Cities - IIoT' Account and @BigDataExpo has been named fourteenth by Right Relevance (RR), which provides curated information and intelligence on approximately 50,000 topics. In addition, Right Relevance provides an Insights offering that combines the above Topics and Influencers information with real time conversations to provide actionable intelligence with visualizations to enable decision making. The Insights service is applicable to eve...
Apr. 26, 2017 05:15 PM EDT Reads: 2,775
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Apr. 26, 2017 05:00 PM EDT Reads: 916
Back in February of 2017, Andrew Clay Schafer of Pivotal tweeted the following: “seriously tho, the whole software industry is stuck on deployment when we desperately need architecture and telemetry.” Intrigue in a 140 characters. For me, I hear Andrew saying, “we’re jumping to step 5 before we’ve successfully completed steps 1-4.”
Apr. 26, 2017 04:30 PM EDT Reads: 1,767
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Apr. 26, 2017 04:15 PM EDT Reads: 556
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Apr. 26, 2017 03:15 PM EDT Reads: 1,427